Clinical Trials Browser

Terminated × Breast Neoplasms × pegfilgrastim × Clear all

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2 Terminated

15 enrolled 9 charts

Breast Neoplasms

NCT02685111 2020-07-31

Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Phase 2 Terminated

BreastClassical hematology

Breast Neoplasms, Neutropenia, Febrile Neutropenia

NCT00080626 2019-03-21

Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT00063934 2019-03-05

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

31 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02650635 2018-09-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01498588 2016-10-03

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 7 charts

Breast Neoplasms

NCT00346229 2016-03-22

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Inflammatory Breast Neoplasms